CytomX to Present at Upcoming Healthcare Conferences
September 25 2018 - 8:00AM
CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage
oncology-focused biopharmaceutical company pioneering a novel class
of investigational antibody therapeutics based on our Probody™
therapeutic technology platform, announced today that members of
its senior management team will participate at the following
healthcare at conferences in October.
Third Annual FierceBiotech Drug Development
Forum
Date: Tuesday, October 2, 2018 Location: Boston,
Massachusetts
- Sean McCarthy, D.Phil., chief executive officer, will
participate in the panel discussion “Develop Combination Therapies
for Immuno-Oncology”
- Debanjan Ray, chief financial officer, will participate in the
panel discussion “Update Collaboration Models Between Pharma and
Biotech”
Cantor Fitzgerald Global Healthcare
Conference
Date: Wednesday, October 3, 2018 Time: 1:05pm EDT Location: New
York, New York
A live audio webcast of the Cantor presentation will be
available through the Investors and News section of CytomX's
website. An archived replay will be available for 90 days following
the event.
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage oncology-focused
biopharmaceutical company pioneering a novel class of
investigational antibody therapeutics based on its Probody™
therapeutic technology platform. Probody therapeutics are designed
to exploit unique conditions of the tumor microenvironment to more
effectively localize antibody binding and activity while limiting
activity in healthy tissues. The Company’s pipeline includes cancer
immunotherapies against clinically-validated targets, including a
PD-L1-targeting Probody therapeutic wholly owned by CytomX
(CX-072), a PD-1-targeting Probody therapeutic wholly owned by
CytomX (CX-188) and a CTLA-4-targeting Probody therapeutic
partnered with Bristol Myers Squibb (BMS-986249). The pipeline also
includes first-in-class Probody drug conjugates against highly
attractive targets including a CD166-targeting Probody drug
conjugate wholly owned by CytomX (CX-2009), and a CD71-targeting
Probody drug conjugate partnered with AbbVie (CX-2029) are among
cancer targets that have been considered to be inaccessible to
conventional antibody drug conjugates due to their presence on many
healthy tissues. CytomX and its partners have four programs in the
clinic. In addition to its wholly owned programs, CytomX has
strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb
Company and ImmunoGen, Inc. For more information, visit
www.cytomx.com.
Contact: Investors and Media: Christopher Keenan VP, Investor
Relations and Corporate Communications ckeenan@cytomx.com
650-383-0823
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Sep 2023 to Sep 2024